ArticleNeurobiology of aging2019
Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers.
Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Neurobiology of aging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02372773 (Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects), which is not on this map. Cited by 13 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 18 citations in OpenAlex.
- Pre-symptomatic radiological changes in frontotemporal dementia: propagation characteristics, predictive value and implications for clinical trials.Brain imaging and behavior · 2022Pooled it
- Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Pooled it
- Structural and functional connectivity in tau mutation carriers: from presymptomatic to symptomatic frontotemporal dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Polypathologic Associations with Gray Matter Atrophy in Neurodegenerative Disease.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2024Article
- Neurite-based white matter alterations in MAPT mutation carriers: A multi-shell diffusion MRI study in the ALLFTD consortium.Neurobiology of aging · 2024Article
- Structural MRI predicts clinical progression in presymptomatic genetic frontotemporal dementia: findings from the GENetic Frontotemporal dementia Initiative cohort.Brain communications · 2023Article
- White-matter abnormalities in presymptomaticBrain communications · 2023Article
- Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases.Brain : a journal of neurology · 2022Article
- Clinical and Neuroimaging Aspects of Familial Frontotemporal Lobar Degeneration Associated with MAPT and GRN Mutations.Advances in experimental medicine and biology · 2021Review
- Brain volumetric deficits in MAPT mutation carriers: a multisite study.Annals of clinical and translational neurology · 2021Article
- Neuroimaging in genetic frontotemporal dementia and amyotrophic lateral sclerosis.Neurobiology of disease · 2020Review
- Imaging Biomarkers for Neurodegeneration in Presymptomatic Familial Frontotemporal Lobar Degeneration.Frontiers in neurology · 2020Review
- Recent advances in understanding frontotemporal degeneration.F1000Research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
67 authors at 20 institutions in 3 countries.
Qin ChenDepartment of Neurology, West China Hospital of Sichuan University, Chengdu, Sichuan, China; Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Bradley F BoeveDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Christopher G SchwarzDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Robert ReidDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Nirubol TosakulwongDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Timothy G LesnickDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Jessica BoveDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Patrick BrannellyTau Consortium, Rainwater Charitable Foundation, Fort Worth, TX, USA.
Danielle BrushaberDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Giovanni CoppolaDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Christina DheelDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Bradford C DickersonDepartment of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
Susan DickinsonAssociation for Frontotemporal Degeneration, Radnor, PA, USA.
Kelley FaberNational Cell Repository for Alzheimer's Disease (NCRAD), Indiana University, Indianapolis, IN, USA.
Julie FieldsDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Jamie FongDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Tatiana ForoudNational Cell Repository for Alzheimer's Disease (NCRAD), Indiana University, Indianapolis, IN, USA.
Leah ForsbergDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Ralitza H GavrilovaDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Debra GearhartDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Nupur GhoshalDepartments of Neurology and Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
Jill GoldmanDepartment of Neurology, Columbia University, New York, NY, USA.
Jonathan Graff-RadfordDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Neill R Graff-RadfordDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Murray GrossmanDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Dana HaleyDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Hilary W HeuerDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Ging-Yuek R HsiungDivision of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Edward HueyDepartment of Neurology, Columbia University, New York, NY, USA.
David J IrwinDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
David T JonesDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Lynne JonesDepartment of Radiology, Washington University School of Medicine, Washington University, St. Louis, MO, USA.
Anna M KarydasDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
David S KnopmanDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
John KornakDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Joel KramerDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Walter KremersDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Walter A KukullNational Alzheimer Coordinating Center (NACC), University of Washington, Seattle, WA, USA.
Maria LapidDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Diane LucenteDepartment of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
Codrin LunguNational Institute of Neurological Disorders and Stroke (NINDS), Bethesda, MD, USA.
Ian R A MackenzieDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Masood ManoochehriDepartment of Neurology, Columbia University, New York, NY, USA.
Scott McGinnisDepartment of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
Bruce L MillerDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Rodney PearlmanBluefield Project, San Francisco, CA, USA.
Leonard PetrucelliDepartment of Neurosciences, Mayo Clinic, Jacksonville, FL, USA.
Madeline PotterNational Cell Repository for Alzheimer's Disease (NCRAD), Indiana University, Indianapolis, IN, USA.
Rosa RademakersDepartment of Neurosciences, Mayo Clinic, Jacksonville, FL, USA.
Eliana M RamosDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA, USA.
Katherine P RankinDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Katya RascovskyDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Pheth SengdyDivision of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
Leslie ShawDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Jeremy SyrjanenDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Nadine TattonAssociation for Frontotemporal Degeneration, Radnor, PA, USA.
Joanne TaylorDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Arthur W TogaDepartments of Ophthalmology, Neurology, Psychiatry and the Behavioral Sciences, Laboratory of Neuroimaging (LONI), USC, Los Angeles, CA, USA.
John TrojanowskiDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Sandra WeintraubDepartment of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Bonnie WongDepartment of Neurology, Frontotemporal Disorders Unit, Massachusetts General Hospital, Harvard University, Boston, MA, USA.
Adam L BoxerDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Howie RosenDepartment of Neurology, Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA.
Zbigniew WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, FL, USA.
Kejal KantarciDepartment of Radiology, Mayo Clinic, Rochester, MN, USA. Electronic address: kantarci.kejal@mayo.edu.
LEFFTDS Consortium
Mayo Clinic in Arizona · USMayo Clinic in Florida · USUniversity of California, San Francisco · USUniversity of Pennsylvania · USWinnMed · USColumbia University · USHarvard University · USIndiana University – Purdue University Indianapolis · USUniversity Memory and Aging Center · USUniversity of British Columbia · CAAssociation for Frontotemporal Degeneration · USBluefield College · USMassachusetts General Hospital · USMayo Clinic · USNational Institute of Neurological Disorders and Stroke · USNeurobehavioral Systems · USNorthwestern University · USRainwater Charitable Foundation · USSichuan University · CNUniversity of California, Los Angeles · US
Funding
Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI Bradley F Boeve · 2019 to 2026
$120.9MNational Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)U24AG021886 · NIA · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI TATIANA M. FOROUD · 2002 to 2026
$119.8MNATIONAL ALZHEIMERS COORDINATING CENTER (NACC)U01AG016976 · NIA · UNIVERSITY OF WASHINGTON · PI KUKULL, WALTER ANTHONY · 1999 to 2020
$72.8MTDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2MNational Alzheimer's Coordinating CenterU24AG072122 · NIA · UNIVERSITY OF WASHINGTON · PI STEPHENS, KARI A · 2021 to 2025
$45.8MTransgenic Mouse Models of Tau PathologiesP01AG017586 · NIA · UNIVERSITY OF PENNSYLVANIA · PI LEE, VIRGINIA M · 2000 to 2021
$37.3MTHE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9MResearch Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI STEVEN E ARNOLD · 2019 to 2026
$36.5MResearch Education ComponentP30AG062677 · NIA · MAYO CLINIC ROCHESTER · PI NILUFER ERTEKIN-TANER · 2019 to 2026
$33.5MNeuropathology CoreP30AG013854 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROGALSKI, EMILY J · 1996 to 2020
$28.9MLongitudinal Imaging Biomarkers of Prodromal DLBU01NS100620 · NINDS · MAYO CLINIC ROCHESTER · PI Bradley F Boeve, KEJAL KANTARCI · 2017 to 2026
$19.2MLongitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS)U01AG045390 · NIA · MAYO CLINIC ROCHESTER · PI BOEVE, BRADLEY F, ROSEN, HOWARD J · 2014 to 2018
$16.9MNIA NIH HHS K24 AG045333NIA NIH HHS P01 AG017586NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG013854NIA NIH HHS P30 AG062421NIA NIH HHS P30 AG062677NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG040042NIA NIH HHS RF1 AG057547NIA NIH HHS U01 AG016976NIA NIH HHS U01 AG045390NIA NIH HHS U19 AG063911NIA NIH HHS U24 AG021886NIA NIH HHS U24 AG072122NINDS NIH HHS U01 NS100620NINDS NIH HHS U54 NS092089
Abstract
Our aim was to investigate the patterns and trajectories of white matter (WM) diffusion abnormalities in microtubule-associated protein tau (MAPT) mutations carriers. We studied 22 MAPT mutation carriers (12 asymptomatic, 10 symptomatic) and 20 noncarriers from 8 families, who underwent diffusion tensor imaging (DTI) and a subset (10 asymptomatic, 6 symptomatic MAPT mutation carriers, and 10 noncarriers) were followed annually (median = 4 years). Cross-sectional and longitudinal changes in mean diffusivity (MD) and fractional anisotropy were analyzed. Asymptomatic MAPT mutation carriers had higher MD in entorhinal WM, which propagated to the limbic tracts and frontotemporal projections in the symptomatic stage compared with noncarriers. Reduced fractional anisotropy and increased MD in the entorhinal WM were associated with the proximity to estimated and actual age of symptom onset. The annualized change of entorhinal MD on serial DTI was accelerated in MAPT mutation carriers compared with noncarriers. Entorhinal WM diffusion abnormalities precede the symptom onset and track with disease progression in MAPT mutation carriers. Our cross-sectional and longitudinal data showed a potential clinical utility for DTI to track neurodegenerative disease progression for MAPT mutation carriers in clinical trials.
Indexed as
AdultAgedDiffusion Magnetic Resonance ImagingDiffusion Tensor ImagingDisease ProgressionFemaleFrontotemporal DementiaGray MatterHeterozygoteHumansMaleMiddle AgedMutationNeurodegenerative DiseasesNeuropsychological Teststau ProteinsMAPT protein, humantau ProteinsAsymptomaticDiffusion tensor imageFrontotemporal dementiaLongitudinalMAPT
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT02372773ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.